



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 638 073 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
21.06.2000 Bulletin 2000/25

(51) Int. Cl.⁷: **C07D 241/04, C07D 241/38,
C07D 487/04**

(21) Application number: **93909807.5**

(86) International application number:
PCT/DK93/00136

(22) Date of filing: **23.04.1993**

(87) International publication number:
WO 93/22293 (11.11.1993 Gazette 1993/27)

(54) **1-PIPERAZINO-1,2-DIHYDROINDENE DERIVATIVES**

**1-PIPERAZINO-1,2-DIHYDROINDENDERIVATE
DERIVES DE 1-PIPERAZINO-1,2-DIHYDROINDENE**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **28.04.1992 DK 55192**

(43) Date of publication of application:
15.02.1995 Bulletin 1995/07

(73) Proprietor: **H. LUNDBECK A/S
2500 Kobenhavn-Valby (DK)**

(72) Inventors:
• **BOGESO, Klaus
DK-2970 Horsholm (DK)**
• **BREGNEDAL, Peter
DK-3450 Allerød (DK)**

(74) Representative:
**Meldahl Petersen, John et al
c/o H. Lundbeck A/S
Patent Department
Ottilavej 7-9
2500 Copenhagen-Valby (DK)**

(56) References cited:
**EP-A- 0 202 322 EP-A- 0 465 398
WO-A-92/00070 WO-A-92/10192
US-A- 4 443 448 US-A- 4 684 650**

- **BOGESO, K.P. ET AL.: "Antihypertensive activ in
a series of 1-piperazino-3-phenylindans potent
5-HT₂-antagonistic activity", J.MED.CHEM.,
WASHINGTON, vol. 31, no. 12, pages 2247 to
2256**
- **PERREGAARD, J. ET AL.: "Noncataleptogenic
centrally acting dopamine D-2 and serotonin 5-
HT₂ antagonists within a series of 3-
substituted", J.MED.CHEM., WASHINGTON, 35,
no. 6, pages 1092 to 1101**


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 638 073 B1

Description

[0001] The present invention relates to novel 1-piperazino-1,2-dihydroindene derivatives and acid addition salts thereof with activity at dopamine receptors in the central nervous system, in particular potent antagonistic action on dopamine D₁ (DA D₁) receptors, to medicaments comprising such derivatives as active ingredients, and to the use of such derivatives in the treatment of diseases in the central nervous system.

[0002] The novel 1-piperazino-1,2-dihydroindene derivatives of the invention are trans isomers (with respect to the indane ring system) represented by the following formula I:



wherein

X is hydrogen, halogen, trifluoromethyl or C₁₋₄ alkyl;

Y is hydrogen or halogen;

Ar is a phenyl group or a phenyl group substituted with halogen, or Ar is a thienyl group;

R¹ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkyl substituted with hydroxy;

R² is C₁₋₄ alkyl; or

R¹ and R² together with the nitrogen and carbon atoms, respectively, to which they are attached form a piperidino ring fused with the piperazine ring, which piperidino ring may optionally be substituted with hydroxy;

R³ is hydrogen or C₁₋₄ alkyl; or

R² and R³ together with the carbon atom to which they are attached form a 3 to 7 membered spirocycloalkyl ring; provided that R² and R³ may not form a ring when R¹ and R² together form a ring.

[0003] The term C₁₋₄ alkyl is intended to mean a straight or branched alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, ect.

[0004] Related 1-piperazino-3-phenylindans being unsubstituted on the piperazine ring carbon atoms and showing potential neuroleptic activity have previously been described in US patent No. 4,443,448. Neuroleptic activity was measured as the ability of the compounds to block stereotypes induced by methylphenidate or amphetamine and as the ability to induce catalepsy. Though today regarded as indicating side-effects, catalepsy nevertheless indicate dopaminergic activity. Some of the compounds were also found to show effect as dopamine uptake inhibitors. Later, DA D₂ receptor binding data for some of these compounds were reported (K.P.Bøgesø, J.Med.Chem. 1983, 26, 935-947) showing a high affinity for D₂ receptors. Furthermore, DA D₁ receptor affinity, measured as inhibition of ³H-piflutixol binding, of one compound from this series, i.e. tefludazine, has been reported to be substantially lower than the D₂ affinity measured as the inhibition of ³H-spiperone binding (O. Svensen et al, Drug. Dev. Res. 1986, 7, 35-47).

[0005] Other 1-piperazino-3-phenylindans are disclosed in US patent No. 4,684,650. These compounds have been shown to be selective 5-HT₂ antagonists, which are inactive or only weakly active as DA antagonists *in vivo* (methylphenidate antagonism). D₂ receptor affinity data for this series were reported by K. P. Bøgesø et al in J. Med. Chem. 1988, 31, 2247-2256 and as expected they had much lower affinity for D₂ receptors than for 5-HT₂ receptors. The D₁ affinity for one compound, irindalone (measured as inhibition of ³H-SCH 23390 binding) was even lower than the D₂ affinity (Hytel et al, Drug. Dev. Res. 1988, 15, 389-404).

[0006] A profile of mixed DA D₁/D₂ receptor inhibition has been observed with some known so-called "atypical" neu-

roleptic compounds, in particular with clozapine, for which such activities have been shown in animal models measuring effects on D₁ and D₂ receptors (J. Arnt and J. Hyttel; *J. Neural Transmission* 1986, 67, 225-240.). Furthermore, ligand binding studies in vitro and in vivo support this observation (J. Hyttel and J. Arnt; *Neurobiology of Central D₁ dopamine receptors*, Plenum Publishing Corporation, 1986. P. H. Andersen; *Eur. J. Pharm.* 1988, 146, 113-120).

5 [0007] Recently, the mixed occupancy of D₁ and D₂ receptors by clozapine has been shown by PET scanning experiments in schizophrenic patients (G. Sedvall; *TINS* 1990, 13, 302-308.). The advantage of mixed D₁/D₂ activity is that lower occupancy of each receptor type apparently is necessary in order to control psychosis. For selective D₂ antagonists (like haloperidol or perphenazine) higher occupancies of D₂ receptors are necessary, but these are accompanied by extrapyramidal side effects (G. Sedvall, 1990, see above).

10 [0008] In addition to D₁ and D₂ receptor activity, clozapine has also high affinity for 5-HT₂ receptors. This effect is at present believed to have a positive influence on the negative symptoms in schizophrenic patients, based upon studies of the 5-HT₂ and moderate dopamine receptor antagonist setoperone (Ceulemans et al.; *Psychopharmacology* 1985, 85, 329-332).

[0009] The selective 5-HT₂ antagonist ritanserlin has been shown to be an antidepressant and to improve depressive symptoms of schizophrenia (E. Klierer, W. H. Strauss; *Pharmacopsychiat.* 1988, 21, 391-393) and it has been demonstrated to exert effects in an animal test reminiscent of anxiolytic activity (F.C. Colpart et al.; *Psychopharmacology* 1985, 86, 303-305). Furthermore ritanserlin has been shown to improve the quality of sleep (P.A.J. Janssen; *Pharmacopsychiat.* 1988, 21, 33-37).

[0010] Furthermore, animal experiments have indicated that 5-HT₂ receptor antagonism might reduce the incidence of extrapyramidal side effects induced by classical neuroleptics (Balsara et al.; *Psychopharmacology* 1979, 62, 67-69) and ritanserlin has been found to relieve neuroleptic-induced parkinsonism (Bersani et al.; *Clinical Neuropharmacology*, 13, No. 6 (1990), 500-506).

[0011] Finally, it is known that 5-HT is involved in migraine attacks. The links between 5-HT and migraine attacks are several and they suggest a number of mechanisms whereby 5-HT may be involved (Scrip Report; "Migraine - Current trends in research and treatment"; PJB Publications Ltd.; May 1991). Various 5-HT₂ antagonists are in clinical trials as anti-migraine agents, such as sergolexole (c.f. for example Pharma Projects, May 1991, 1359-1365).

25 [0012] It has been shown (J. Seibyl et al., Abstr. no 148.6, 21st Annual Meeting Society for Neuroscience, New Orleans, November 10-15, 1991) that the DA uptake inhibitor mazindol may be a useful adjunct to standard neuroleptic medication for treating refractory negative symptoms in otherwise stable outpatient schizophrenics.

[0013] Furthermore, DA uptake inhibitors may be useful in the treatment of Parkinson's disease, as antidepressant agents or in treatment of cocaine dependence. Possible effect in Parkinson's disease is based on the fact that DA uptake inhibitors are effective in preventing the nigrostriatal toxicity of the neurotoxin MPTP (R. A. Mayer et al., *J. Neurochem.* 1986, 47, 1073-1079), and that MPTP like substances or other neurotoxins utilizing the DA uptake carrier might be involved in development of Parkinson's disease.

35 [0014] Dopamine may play an important role in the etiology of affective disorders (P. Willner, *Brain. Res. Rev.* 1983, 6, 211-224, 225-236 and 237-246; K. P. Bøgesø, *J. Med. Chem.*, 1985, 28, 1817-1828) and DA uptake inhibitors are believed to be effective in treatment of depression (W. Jansen, *Pharmacopsychiat.* 1982, 15, 205-209; H. J. Funke, *Pharmacopsychiat.*, 1986, 19, 120-123).

[0015] The stimulant and widely abused drug cocaine is an inhibitor of DA uptake. It has been shown that the potencies of cocaine and cocaine analogs in self-administration studies correlates well with their DA uptake inhibiting potency (M. C. Ritz, *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, 1988, 12, 233-239). In squirrel monkeys DA uptake inhibitors show behavioral effects similar to cocaine (S. Rosenzweig-Lipson et al., *Psychopharmacology*, 1992, 107, 186-194). However, in humans, cocaine administered intravenously or by inhalation, has a fast onset and relatively short duration of action which is supposed to be an important part of its stimulating effect. DA uptake inhibitors with different pharmacokinetic properties might not have similar addictive potential and consequently they could be useful in treatment of cocaine addiction and in prevention of relapse (S. Rosenzweig-Lipson et al., *Psychopharmacology*, 1992, 107, 186-194).

45 [0016] It has now surprisingly been found that compounds of the above defined Formula I have high affinity for D₁ receptors and that in general they have a higher affinity for D₁ receptors than for D₂ receptors. Furthermore they have been shown to have high affinity for 5-HT₂ receptors and only to induce catalepsy in rats in relatively high doses. Finally, many of the compounds have been found to have dopamine uptake inhibiting effect.

[0017] The above evidence with respect to effects of substances having a mixed D₁/D₂ profile indicates that the present compounds are useful as neuroleptics with effect on psychosis, including positive symptoms of schizophrenia. Additionally, the 5-HT₂ receptor antagonistic activity suggests that the compounds have a low risk of extrapyramidal side effects (as also evidenced by the relatively weak cataleptogenic effects). 5-HT₂ antagonism and dopamine uptake inhibiting activities indicate that they may also have a beneficial effect on negative symptoms of schizophrenia. So, the present compounds have proven to be very promising neuroleptics with a low incidence of extrapyramidal side effects.

55 [0018] Furthermore, the 5-HT₂ receptor antagonistic activity indicates that they may also have an effect on anxiety,

depression, sleep disturbances, migraine, and Parkinson's disease (Parkinsonian syndrome) whereas the dopamine uptake inhibition with or without concomitant dopamine antagonistic activity show that they may be effective in the treatment of cocaine abuse. Additionally, the dopamine uptake inhibition indicate that they may be useful in the treatment of Parkinson's disease and depression.

5 [0019] Only trans-isomers of the 1-piperazinoindan derivatives of Formula I are active, cis-isomers being without significant activity.

[0020] Accordingly, in a first aspect the present invention relates to trans-isomers of the compounds having the general Formula I as defined above and prodrugs therefore and pharmaceutically acceptable acid addition salts thereof.

10 [0021] The trans-isomers, with respect to the indan ring system, of the invention exist as pairs of optically active isomers and such isomers are within the scope of the present invention. It has so far been found that the D₁ (and 5-HT₂) antagonistic activity predominantly resides in one of the optical isomers whereas the dopamine uptake inhibiting properties reside in the opposite enantiomer. In certain cases also the piperazine ring of compounds of Formula I contains chiral carbon atoms. The resulting stereoisomers are also within the scope of the invention.

15 [0022] Prodrugs of the present invention are i.a. esters with available hydroxy groups. These esters will decompose properly in order to release the compound of the invention over a desired period of time when administered parenterally as a depot formulation in an appropriate oil, such as coconut oil, e.g. viscoleo[®], peanut oil, sesame oil, cotton seed oil, corn oil, soy bean oil, olive oil, etc. or synthetic esters of fatty acids and glycerol or propylenglycol.

20 [0023] The pharmaceutically acceptable acid addition salts of the compounds of the invention are salts formed with non-toxic organic or inorganic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

25 [0024] As mentioned above the present invention relates to compounds of formula I wherein

X is hydrogen, halogen, trifluoromethyl or C₁₋₄ alkyl;

Y is hydrogen or halogen;

Ar is a phenyl group or a phenyl group substituted with halogen, or Ar is a thienyl group;

30 R¹ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkyl optionally substituted with hydroxy; R² is C₁₋₄ alkyl; or R¹ and R² together with the nitrogen and carbon atoms, respectively, to which they are attached form a piperidino ring fused with the piperazine ring, which piperidino ring may optionally be substituted with hydroxy; and

R³ is hydrogen or C₁₋₄ alkyl; or R² and R³ together with the carbon atom to which they are attached form a 3 to 7 membered spirocycloalkyl ring; provided that R² and R³ may not form a ring when R¹ and R² together form a ring.

35 [0025] Particularly preferred compounds are those wherein:

X is hydrogen, a chloro, bromo or fluoro atom, methyl or trifluoromethyl;

Y is hydrogen;

40 Ar is phenyl, fluorophenyl or thienyl;

R¹ is hydrogen, methyl, 2-propyl, hydroxypropyl or hydroxyethyl;

R² is methyl, ethyl or 2-propyl and R³ is hydrogen, methyl or ethyl ; or

R² and R³ together with the carbon atoms to which they are attached form a spirocyclobutyl or a spirocyclopentyl ring.

45 [0026] In a second aspect the present invention relates to a medical preparation comprising at least one derivative of the general Formula I as defined above or a prodrug or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier or diluent. As seen from the above such a pharmaceutical preparation may conveniently comprise a pure enantiomer, a racemate or any other mixture of two enantiomers.

50 [0027] In a further aspect the present invention relates to a method for the treatment of a disease in the central nervous system, preferably psychosis, schizophrenia (positive as well as negative symptoms), anxiety, depression, sleep disturbances, migraine, Parkinson's disease or cocaine abuse, comprising the step of administering a therapeutically effective dose of a compound having the general Formula I as defined above or a prodrug therefore or a pharmaceutically acceptable acid addition salt thereof together with a suitable carrier or diluent to a patient in need thereof.

55 [0028] The compounds of the Formula I and the pharmaceutically acceptable acid addition salts thereof may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection.


[0029] Suitable pharmaceutical preparations may be prepared by methods well known in the art. Conveniently, the

compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.05 - 100 mg, preferably about 1 - 50 mg.


[0030] The total daily dose usually ranges from about 0.1 to 500 mg of the active compound of the invention.

[0031] The invention moreover relates to a method for the preparation of the novel derivatives of Formula I, which comprises:

a) treating a compound of the Following formula II:




with a piperazine derivative of Formula III:




in which formulas X, Y, Ar, R₁, R₂, R₃ and R₄ are as defined above, and Z is halogen or -OSO₂R₆ wherein R₆ is alkyl such as CH₃ or aryl such as p-tolyl;

b) treating a compound of the following Formula IV:



wherein X, Y, Ar, R₂, R₃ and R₄ are as defined above, with a compound of the formula R₁-Z wherein R₁ and Z are as defined above except that R₁ cannot be hydrogen, or with an epoxide of formula




wherein R' is hydrogen, methyl, ethyl, ethenyl, cycloalkyl or cycloalkylalkyl;

c) treating a compound of Formula IV with a compound R"-CHO, wherein R" is hydrogen, C₁-C₃ alkyl, C₂-C₃ alkenyl, cycloalkyl or cycloalkylalkyl in the presence of a reducing agent;


d) treating a compound of Formula IV with HCHO/HCOOH to produce derivatives of Formula I wherein R₁ = methyl (Eschweiler-Clarke methylation);

e) reducing a compound of Formula V:



wherein X, Y, Ar, R₂, R₃ and R₄ are as defined above and R' is hydrogen, lower alkoxy, C₁-C₃ alkyl, C₂-C₃ alkenyl, cycloalkyl or cycloalkylalkyl;

f) reducing a compound of Formula VI:



wherein X, Y and Ar are as defined above and one or more of the substituents R'₁, R'₂, R'₃ and R'₄ contain one or more ester, ketone or aldehyde groups with a suitable reducing agent to the corresponding compound containing one or more hydroxy groups.

Method a) is preferably carried out in an inert solvent such as acetone or methylisobutylketone using either an excess of the piperazine reactant or by using equimolar amounts of reactants in the presence of an alkali metal carbonate such as potassium carbonate or another alkaline substance at reflux temperatures.

Method b) is preferably carried out in an inert solvent such as ethanol or isobutylketone in the presence of an alkali metal carbonate such as potassium carbonate or another alkaline substance at reflux temperatures.

Method c) is preferably carried out in an inert solvent such as an alcohol (eg methanol) or an ether (eg tetrahydro-

furan) by hydrogenation in the presence of a suitable catalyst such as PtO_2 or Pd or by using a borohydride such as NaCNBH_3 at a pH of 5-6.

Method d) is preferably carried out with an excess of formaldehyde in formic acid at reflux temperatures.

Method e) is preferably carried out in an inert solvent such as diethylether or tetrahydrofurane using a suitable reducing agent such as LiAlH_4 .


Method f) is preferably carried out in an inert solvent such as diethylether or tetrahydrofurane using a suitable reducing agent such as LiAlH_4 or a borohydride e.g. NaBH_4 .

[0032] The acid addition salts of the compounds of the invention are easily prepared by methods well known in the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or with an excess of the acid in an aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts.

[0033] The separation of the compounds of Formula I in the individual optical isomers may be performed by methods well known in the art.

[0034] The compounds of Formula II may be prepared from the corresponding 2,3-dihydro-inden-1-ones by a method analogously with the method described in U.S. Patent No. 4,443,448, U.S. Patent No. 4,684,650, and J. Med. Chem. 1983, 26, 935-947. The indanones were either prepared by cyclization of the corresponding diphenylpropionic acids or more conveniently as described for similar compounds in U.S. Patent No. 4,873,344 and in J. Org. Chem. 1990, 5, 4822 from properly substituted 1-amino-3-cyano-1-inden-2-carboxylic acid esters which in turn also may be prepared as described in U.S. Patent No. 4,873,344.

[0035] Some piperazine derivatives III are commercially available (2-methylpiperazine, 2,5-dimethylpiperazine and 2,6-dimethylpiperazine) while other piperazines were prepared by methods established in the literature: 2-isopropylpiperazine (Beilstein 3 & 4 ergänzungswerk, 23, 430 and references cited there); octahydropyrido[1,2-a]pyrazine, IIIa (Peck R. L. and Day A. R.; J. Heterocycl. Chem. 1969, 6, 181-185).



[0036] 1,4-Diazaspiro[5.5]undecane, IIIb and 6,9-diazaspiro[4.5]decane, IIIc, have been reported in the literature (Granger R. et al; Trav. Soc. Pharm. Montpellier 1965, 25, 313-317) but were like 5,8-diazaspiro[3.5]nonane, IIId, prepared by the same procedure as described for 2,2-dimethylpiperazine and 2,2-diethylpiperazine below.

[0037] Obviously, the compounds of Formula IV may be prepared by method a). The compounds of Formulas V and VI may be prepared from compounds of Formula IV by methods well known in the art.

[0038] In the following the invention is further illustrated by examples which in no way may be construed as limiting for the invention.

EXAMPLES

Example 1

2,2-Dimethylpiperazine.

[0039] To a mixture of isobutyraldehyde (790 g, 10.95 mol) and dioxane (39.5 g, 0.45 mol) in dry ether (4 L) was added 11 mL of bromine at room temperature. The mixture was cooled to 5 °C and further 509 mL (1588 g, 9.93 mol) bromine was added at 5-10 °C. The reaction mixture was poured into 4 L of ice water whereupon sodium carbonate (600 g) was gradually added with stirring. The organic phase was separated, dried (MgSO_4) and distilled to yield 1150 g (69.6%) of 2-bromo-isobutyraldehyde, bp 70-77 °C (170 mm Hg).

2-Bromo-isobutyraldehyde (1070 g, 7.09 mol) was added with vigorous stirring to a mixture of ethylenediamine (2.2 kg,

36.6 mol) and toluene at 5-10 °C. The reaction mixture was stirred at room temperature for 1 h and was then refluxed for 30 min. The toluene phase was separated and the lower phase was extracted twice with 500 mL of toluene. The toluene phase was concentrated in vacuo and the residue was distilled to give 450 g (56.6%) of crude 2,2-dimethyl-1,2,5,6-tetrahydro-pyrazine, bp 80-120 °C (170 mm Hg).

To a solution of the crude 2,2-dimethyl-1,2,5,6-tetrahydropyrazine (450 g) in 1 L ethanol was added 5% Pd/C (20 g) and the reaction mixture was hydrogenated in a Parr apparatus at 3.5 ato until the consumption of hydrogen (2.2 mol) stopped. After filtration the reaction mixture was distilled at atmospheric pressure. The fraction boiling at 140-180 °C was collected and redistilled to yield 159 g (19.8% from 2-bromo-isobutyraldehyde) of 2,2-dimethylpiperazine, bp 150-170 °C (760 mm Hg). ¹H NMR (250 MHz, CDCl₃) δ 1.12 (s, 6H), 1.33 (br s, 2H, NH), 2.60 (s, 2H), 2.76 (t, 2H), 2.85 (t, 2H).

The product solidified upon standing (mp below 35 °C).

[0040] 2,2-Diethylpiperazine and the piperazine derivatives IIIa-d were prepared in a similar manner.

Example 2

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethylpiperazine, hemifumarate, 1.

[0041] A mixture of 1,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-indene (28 g, 0.1 mol), 2,2-dimethylpiperazine (15 g, 0.13 mol) and potassium carbonate (30 g) in acetone (250 mL) was refluxed for 18 h. The reaction mixture was evaporated in vacuo and treated with water and ether. The ether phase was separated and extracted with 1 M methane sulfonic acid. The base was liberated with 10 M sodium hydroxide, extracted with ether and dried (MgSO₄). After filtration and evaporation in vacuo the residue was dissolved in acetone and treated with fumaric acid. The fumarate salt was filtered to give 27 g of 1 as the hemifumarate salt, mp 240-241 °C. A sample recrystallized from ethanol had mp 242-244 °C. Isomeric purity (TLC): 95 % trans isomer (racemate).

CHN calcd.:	66.25%;	6.30%;	6.72%.
CHN found:	66.05%;	6.49%;	6.44%.

Example 3

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, maleate, 2.

[0042] A mixture of the hemifumarate of 1 (23g, 0.055 mol, see Example 1), 37% formaldehyde (100 mL) and formic acid (100 mL). The clear solution was heated on a steam bath for 2 h and was then evaporated in vacuo. The residue was converted to the base in a conventional manner. The base was dissolved in ethyl acetate and treated with maleic acid. The maleate was recrystallized from ethyl acetate to give 13.5 g (50%) of 2, maleate, mp 143-146 °C. Isomeric purity (TLC): >98% trans isomer (racemate).

CHN calcd.:	63.85%;	6.20%;	5.73%.
CHN found:	63.77%;	6.27%;	5.65%.

[0043] The methods described in Example 2 and Example 3 (N-methyl derivatives) were used for the preparation of the following compounds:

- (±)-Trans-4-[3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethyl-piperazine, dimaleate; mp 162-165 °C. Compd. 3.
- (±)-Trans-2,2-dimethyl-4-[6-methyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazine; mp 108-110 °C. Compd. 4.
- (±)-Trans-4-[6-methyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine; mp 119-121 °C. Compd. 5.
- (±)-Trans-2,2-dimethyl-4-[6-trifluoromethyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazine; mp 94-95 °C. Compd. 6.
- (±)-Trans-4-[6-trifluoromethyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine; mp 112-114

- °C. Compd. 7.
- (±)-Trans-4-[6-bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, 1,5 fumarate; mp 142-145 °C. Compd. 8.
- 5 (±)-Trans-4-[5,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, 1,5 fumarate; mp 182-184 °C. Compd. 9.
- (±)-Trans-4-[6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, 1,5 maleate; mp 170-171 °C. Compd. 10.
- (±)-Trans-4-[6-chloro-3-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dimaleate; mp 154-156 °C. Compd. 11.
- 10 (±)-Trans-4-[6-chloro-3-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dimaleate; mp 140-142 °C. Compd. 12.
- (±)-Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethylpiperazine, dimaleate; mp 163-165 °C. Compd. 13.
- (±)-Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dihydrochloride; mp 173-176 °C. Compd. 14.
- 15 (±)-Trans-4-[4-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dioxalate; mp 120-125 °C. Compd. 15.
- (±)-Trans-4-[5-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine; mp 126-128 °C. Compd. 16.
- 20 (±)-Trans-4-[7-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, 1,3 oxalate; mp 153-155 °C. Compd. 17.
- (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2-dimethylpiperazine, dimaleate; mp 181-183 °C. Compd. 18.
- Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2-(2-propyl)-piperazine, dimaleate; mp 135-137 °C. Pair 1 of diastereomeric trans isomers. Compd. 19.
- 25 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2-(2-propyl)-piperazine, maleate; mp 156-159 °C. Pair 2 of diastereomeric trans isomers. Compd. 20.
- Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-2-(2-propyl)piperazine, dimaleate; mp 119-122 °C. Pair 1 of diastereomeric trans isomers. Compd. 21.
- 30 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-2-(2-propyl)piperazine, dimaleate; mp 160-162 °C. Pair 2 of diastereomeric trans isomers. Compd. 22.
- (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-diethylpiperazine, fumarate; mp 231-233 °C. Compd. 23.
- (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-diethyl-1-methylpiperazine, oxalate; mp 144-146 °C. Compd. 24.
- 35 (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-trans-2,5-trimethylpiperazine, maleate; mp 166-169 °C. Compd. 25.
- (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-cis-2,6-trimethylpiperazine, dioxalate; mp 158-160 °C. Compd. 26.
- 40 (±)-Trans-4-[6-trifluoromethyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-cis-2,6-dimethylpiperazine, dihydrochloride; mp 255-260 °C. Compd. 27.
- (±)-Trans-8-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-5-methyl-5,8-diazaspiro[3.5]nonane, dihydrochloride; mp 188-190 °C. Compd. 28.
- (±)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane, fumarate; mp 144-147 °C. Compd. 29.
- 45 (±)-Trans-9-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane, dihydrochloride; mp 182-184 °C. Compd. 30.
- (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,4-diazaspiro[5.5]undecane, fumarate; mp 241-243 °C. Compd. 31.
- 50 (±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1,4-diazaspiro[5.5]undecane, dihydrochloride; mp 205-207 °C. Compd. 32.
- 2-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]pyrazine, dihydrochloride; mp 225-227 °C. 1:1 mixture of cis and trans isomers. Compd. 33.
- (±)-Trans-2-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]pyrazine, dimaleate; mp 172-174 °C. Compd. 34.
- 55 2-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]pyrazine-8-ol, dihydrochloride; mp 223-225 °C. 1:1 mixture of cis and trans isomers. Compd. 35.
- (±)-Trans-4-[7-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, oxalate; mp 133-135

°C. Compd. 36.

(±)-Trans-4-[3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazine, dimaleate; mp 135-137 °C. Compd. 37.

(±)-Trans-4-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethyl piperazine, dimaleate; mp 154-156 °C. Compd. 38.

Example 4

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazinepropanol, maleate, 39.

[0044] A mixture of 1 (base, 6 g, 0.017 mol), 3-chloro-1-propanol (1.9 g, 0.020 mol) and potassium carbonate (3 g, 0.021 mol) in ethanol (250 mL) was refluxed overnight. The reaction mixture was worked-up as described in Example 2 to give 6 g of crude base. The base was converted to the maleate salt in ethyl acetate and was recrystallized twice from acetone-ether to give 2.5 g 39, maleate, mp 177-178 °C. Isomeric purity (TLC): 92% trans isomer (racemate).

CHN calcd.:	63.08%;	6.44%;	5.26%.
CHN found:	63.28%;	6.15%;	5.62%.

[0045] The method described in Example 4 were used for the preparation of the following compounds:

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-(2-propyl)piperazine, dioxalate; mp 157-159 °C. Compd. 40

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2-methyl-1-(2-propyl)piperazine, dimaleate; mp 89-92 °C. Compd. 41.

(±)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-6-(2-propyl)-6,9-diazaspiro[4.5]decane, dihydrochloride; mp 237-238 °C. Compd. 42.

Example 5

(±)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazineethanol, 43.

[0046] A mixture of 1 (base, 5.4 g, 0.015 mol), ethyl bromoacetate (3.3 g, 0.020 mol) and potassium carbonate (3 g, 0.021 mol) in methyl isobutylketone was refluxed for 4 h. The reaction mixture was evaporated in vacuo and treated with ether and water. The ether phase was dried (MgSO₄) and evaporated to give 7 g of crude ester. The ester was dissolved in dry ether, LiAlH₄ (2 g) was added and the mixture was refluxed for 3 h. The excess LiAlH₄ was destroyed with water, the organic phase was decanted, and the product was extracted from the ether phase with 1 N methane sulfonic acid. The base was liberated with 10 N NaOH, extracted with ether, dried and evaporated in vacuo. The base crystallized from petroleum ether to yield 1.1 g, mp 79-81 °C. Isomeric purity (TLC): 99% trans isomer (racemate).

CHN calcd.:	68.55%;	7.02%;	6.95%.
CHN found:	68.77%;	7.32%;	6.78%.

[0047] The method described in Example 5 were used for the preparation of the following compounds:

(±)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-6-(2-hydroxyethyl)-6,9-diazaspiro[4.5]decane, dihydrochloride; mp 167-169 °C. Compd. 44.

(±)-Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazineethanol, dihydrochloride; mp 213-215 °C. Compd. 45.

Example 6

(+) and (-) Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, maleate, (+)-2 and (-)-2.

[0048] To a solution of 2 (base, 70 g, 0.187 mol) in 1 L of ethyl acetate was added (+)-O,O'-dibenzoyl-D-tartaric acid hydrate ((+)-DBT, 70.6 g, 0.189 mol). The clear solution was left at room temperature overnight. The crude (+)-DBT salt was filtered, dried (yield 53 g) and recrystallized from ethyl acetate-methanol. The (+)-DBT salt (mp 123-128 °C) was converted to the base which was dissolved in acetone and converted to the hydrochloride. Yield: 13 g of (-)-2, dihydrochloride, mp 201-202 °C; $[\alpha]_D^{22}$ -23.4° (c 0.5, MeOH).

[0049] The first filtrate from the (+)-DBT salt was evaporated in vacuo and converted to the base (38 g), which was dissolved in ethyl acetate and treated with (-)-DBT hydrate (38.3 g) to give the (-)-DBT salt. This was converted to the hydrochloride as described for the (-)-enantiomer. Yield: 14.8 g of (+)-2, dihydrochloride, mp 206-208 °C; $[\alpha]_D^{22}$ +24.5° (c 0.5, MeOH).

CHN calcd.:	59.26%;	6.34%;	6.28%.
CHN found:	59.33%;	6.64%;	6.46% ((-)-2).
CHN found:	59.05%;	6.47%;	6.04% ((+)-2).

[0050] Compound 29, 37, 40 and 44 were separated into their enantiomers using a similar procedure as described in Example 6:

(-)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane, dihydrochloride; mp 204-206 °C; $[\alpha]_D^{22}$ -13.8° (c 1, DMF). Compd. (-)-29.

(+)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane, dihydrochloride; mp 205-207 °C; $[\alpha]_D^{22}$ +10.5° (c 1, DMF). Compd. (+)-29.

(-)-Trans-4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dimaleate; mp 197-199 °C; $[\alpha]_D^{22}$ -2.7° (c 0.5, CH₃OH). Compd. (-)-37.

(+)-Trans-4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine, dimaleate; mp 198-199 °C; $[\alpha]_D^{22}$ -2.5° (c 0.5, CH₃OH). Compd. (+)-37.

(-)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-(2-propyl)-piperazine, dioxalate; mp 169-171 °C. $[\alpha]_D^{22}$ -18.4° (c 1, MeOH). Compd. (-)-40

(+)-Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-(2-propyl)-piperazine, dioxalate; mp 171-172 °C. $[\alpha]_D^{22}$ +18.2° (c 1, MeOH). Compd. (+)-40.

(-)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-(2-hydroxyethyl)-6,9-diazaspiro[4.5]decane, dihydrobromide; mp 197-199 °C. $[\alpha]_D^{22}$ -10.2° (c 1, MeOH). Compd. (-)-44.

(+)-Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-(2-hydroxyethyl)-6,9-diazaspiro[4.5]decane, dihydrobromide; mp 206-208 °C. $[\alpha]_D^{22}$ +10.7° (c 1, MeOH). Compd. (+)-44.

PHARMACOLOGY

[0051] The present compounds were tested in the following well known and reliable pharmacological test methods.

Receptor binding studies.

[0052]

DA D₁ receptors. Inhibition of ³H-SCH 23390 binding to DA D₁ receptors in rat striatal membranes was determined as described by Hyttel, J. and Arnt, J. *J. Neural. Transm.* 1987, 68, 171.

DA D₂ receptors. Inhibition of ³H-spiperone binding to DA D₂ receptors in rat striatal membranes was determined as described by Hyttel, J. *Acta. Pharmacol. Toxicol.* 1986, 59, 387.

5-HT₂ receptors. Inhibition of ³H-ketanserin binding to 5-HT₂ receptors in membranes from rat cortex was deter-

EP 0 638 073 B1

mined as described by Hyttel, J. *Acta. Pharmacol. Toxicol.* **1987**, 61, 126.

[0053] The affinity to D₁, D₂ and 5-HT₂ receptors of the compounds described in the examples above are shown in the following Table 1. The reference compounds tefudazine, irindalone and clozapine were included in the tests for
5 comparizon purposes.

10

15

20

25

30

35

40

45

50

55

TABLE 1
Receptor Binding; IC₅₀ values in nM

Compound	D ₁ ³H-SCH	D ₂ ³H-Spi	5-HT ₂ ³H-Ket
1	2.1	7.3	3.2
2	1.3	25	2.1
-2	0.68	5.0	1.1
+2	620	>1000	2000
3	13	140	21
4	5.9	5.6	1.5
5	2.1	4.8	3.4
6	2.8	5.2	
7	1.5	5.7	4.5
8	1.8	8.6	3.0
9	18	44	5.9
10	1.6	20	3.2
11	4.4	36	21
12	9.6	280	26
13	1.4	8.2	1.0
14	0.76	6.1	1.7
15	45	55	29
16	37	340	9.3
17	32	1200	31
18	2.4	12	
19	2.2	38	5.6
20	6.0	130	8.8
21	3.2	36	
22	43	400	
23	4.7	36	11
24	8.8	38	
25	19	41	3.4
26	13	120	3.3
27	50	33	

TABEL 1 (Cont'd)
Receptor Binding; IC₅₀ values in nM

Compound	D ₁ ³ H-SCH	D ₂ ³ H-Spi	5-HT ₂ ³ H-Ket
28	0.89	6.3	3.0
29	0.85	10	5.2
-29	0.96	4.5	4.0
+29	6.6	20	13
30	1.8	5.0	
31	6.4	75	25
32	6.0	24	
33	5.8	320	28
34	2.1	11	
35	30	1100	
36	3.8	74	9.8
37	3.0	29	5.1
-37	2.5	12	2.9
+37	250	4900	650
38	0.88	11	3.6
39	1.8	9.8	3.0
40	0.82	5.0	4.1
-40	0.66	3.1	2.5
+40	52		
41	1.6	17	
42	1.3	8.8	
43	1.0	3.0	
44	1.9	13	6.0
-44	1.0	5.0	2.5
+44	51		
45	0.82	2.8	
Tefludazine	23	10	4.6
Irindalone	890	400	3.4
Clozapine	130	330	7.8

[0054] The results in the Table show that in general the compounds have very high affinity to D₁ receptors (IC₅₀ values in the low nanomolar range). In most cases the affinity to D₂ receptors is considerably lower. The D₂/D₁ ratio is therefore higher and in many cases considerably higher, than for the reference compound clozapine. Furthermore, it

appears that the compounds have affinity for the 5-HT₂ receptor and data with respect to resolved compounds show that the affinities predominantly reside in one enantiomer.

DA uptake inhibition.

[0055] Inhibition of DA Uptake in Vitro was determined as described by K. P. Bøgesø, *J. Med. Chem.* 1983, 26, 935-947.

[0056] For racemic compounds the IC₅₀ values for inhibition of DA uptake were generally < 1 µmol. Some compounds were active in the low nanomolar range. Thus, IC₅₀ values were 16 nM (compd. (+)-2), 15 nM (compd. 10), 36 nM (compd. 37) and 9 nM (compd. 38; the corresponding prior art compound with an unsubstituted piperazine ring had an IC₅₀ value of 180 nM, see K. P. Bøgesø, *J. Med. Chem.* 1983, 26, 935-947). In resolved compounds the dopamine uptake inhibition was seen to reside mainly in the opposite enantiomer of the above binding affinities.

PHARMACOLOGY IN VIVO

Antagonism of SK&F 38393-induced circling behavior in rats with unilateral 6-OHDA lesions.

[0057] This test is a test for the DA D₁ receptor antagonistic effect *in vivo*.

[0058] The experiments were performed as described by Arnt, J. and Hyttel, J. *J. Neural. Transm.* 1986, 67, 225-240. The experiments were done 2 - 9 months after lesioning when stable contralateral circling response to 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, hydrochloride (SK&F 38393) (4.3 µmol/kg = 1.4 mg/kg) were obtained. The test compounds were injected 2 h before administration of SK&F 38393. Antagonistic effect were calculated as percent inhibition of control responses for each rat. Four to eight animals were used per dose.

Cataleptogenic effect in rats.

[0059] Catalepsy was measured every hour 1-6 h after test drug administration on a vertical wire grid and defined as being present after at least 15-s immobility. The maximum effect between 1-6 h after administration was reported. A total of 8-12 animals were used per dose.

[0060] Most of the compounds were very active as D₁ antagonists *in vivo* (antagonism of SK&F 38393-induced circling behavior). The ED₅₀'s were for many compounds in the range 0.2-2 µmol/kg. For example, the ED₅₀ for compound 38 was 0.50 µmol/kg. For many compounds catalepsy was absent or only induced in doses much higher than the doses needed to antagonize the SK&F 38393-induced circling behavior. The ED₅₀'s in the catalepsy test were typically in the range from 5 to 90 µmol/kg. For compound 38 the ED₅₀ were > 68 µmol/kg. A weak or absent effect in the catalepsy test indicate a low potential for inducing motoric (extrapyramidal) side-effects in man.

FORMULATION EXAMPLES

[0061] The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.

For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents preservatives, antioxidants, etc.

[0062] Typical examples of recipes for the formulation of the invention are as follows:

- 1) Tablets containing 5 milligrams of Compound 38 calculated as the free base:

Compn. 38	2 mg
Lactose	18 mg

EP 0 638 073 B1

(continued)

Potato starch	27 mg
Sucrose	58 mg
Sorbitol	3 mg
Talcum	5 mg
Gelatine	2 mg
Povidone	1 mg
Magnesium stearate	0.5 mg

2) Tablets containing 50 milligrams of Compound 28 calculated as the free base:

Compn. 28	5 mg
Lactose	16 mg
Potato starch	45 mg
Sucrose	106 mg
Sorbitol	6 mg
Talcum	9 mg
Gelatine	4 mg
Povidone	3 mg
Magnesium stearate	0.6 mg

3) Syrup containing per milliliter:

Compn. 2	10 mg
Sorbitol	500 mg
Tragacanth	7 mg
Glycerol	50 mg
Methyl-paraben	1 mg
Propyl-paraben	0.1 mg
Ethanol	0.005 ml
Water	ad 1 ml

4) Solution for injection containing per milliliter:


Compn. 14	50 mg
Acetic acid	17.9 mg
Sterile water	ad 1 ml

5) Solution for injection containing per milliliter:

Comp. 29	10 mg
Sorbitol	42.9 mg
Acetic acid	0.63 mg
Sodium hydroxide	22 mg
Sterile water	ad 1 ml

Claims

1. Trans isomers of 1-piperazino-1,2-dihydroindene compounds having the general formula I:



wherein

X is hydrogen, halogen, trifluoromethyl or C₁₋₄ alkyl;

Y is hydrogen or halogen;

Ar is a phenyl group or a phenyl group substituted with halogen, or Ar is a thienyl group;

R¹ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkyl substituted with hydroxy;

R² is C₁₋₄ alkyl; or

R¹ and R² together with the nitrogen and carbon atoms, respectively, to which they are attached form a piperidino ring fused with the piperazine ring, which piperidino ring may optionally be substituted with hydroxy;

R³ is hydrogen or C₁₋₄ alkyl; or

R² and R³ together with the carbon atom to which they are attached form a 3 to 7 membered spirocycloalkyl ring;

provided that R² and R³ may not form a ring when R¹ and R² together form a ring; as well as pharmaceutically acceptable acid addition salts thereof.

2. A compound according to Claim 1, characterized in that

X is hydrogen, a chloro, bromo or fluoro atom, methyl or trifluoromethyl;

Y is hydrogen;

Ar is phenyl, fluorophenyl or thienyl;

R¹ is hydrogen, methyl, 2-propyl, hydroxypropyl or hydroxyethyl;

R² is methyl, ethyl or 2-propyl and R³ is hydrogen, methyl or ethyl; or

R² and R³ together with the carbon atoms to which they are attached form a spirocyclobutyl or a spirocyclopentyl ring.


3. The compound according to claim 1, said compound being

Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethylpiperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-2,2-dimethyl-4-[6-methyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazine;
 5 Trans-4-[6-methyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-2,2-dimethyl-4-[6-trifluoromethyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazine;
 Trans-4-[6-trifluoromethyl-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[5,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 10 Trans-4-[6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-chloro-3-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-chloro-3-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethylpiperazine;
 Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 15 Trans-4-[4-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[5-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[7-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2-dimethylpiperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2-(2-propyl)-piperazine;
 20 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-2-(2-propyl)piperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-diethylpiperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-diethyl-1-methylpiperazine;
 Trans-8-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-5-methyl-5,8-diazaspiro[3.5]nonane;
 Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane;
 25 Trans-9-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decane;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,4-diazaspiro[5.5]undecan;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1,4-diazaspiro[5.5]undecan;
 2-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]-pyrazine;
 Trans-2-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]pyrazine;
 30 2-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-octahydropyrido[1,2-a]-pyrazine-8-ol;
 Trans-4-[7-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-piperazinepropanol;
 35 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-(2-propyl)piperazine;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2-methyl-1-(2-propyl)piperazine;
 Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-(2-propyl)-6,9-diazaspiro[4.5]decane;
 Trans-4-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-piperazineethanol;
 Trans-9-[6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-6-(2-hydroxy-ethyl)-6,9-diaza-
 40 spiro[4.5]decane;
 Trans-4-[6-chloro-3-(3-thienyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-1-piperazineethanol;

4. A pharmaceutical preparation, characterized in that it comprises at least one compound according to Claim 1 together with a pharmaceutically acceptable carrier or diluent.
5. A pharmaceutical preparation according to Claim 4, characterized in that the compound according to Claim 1 is present as a pure enantiomer, a racemate or any other mixture of the two enantiomers.
6. Use of a compound according to Claim 1 for the manufacture of a pharmaceutical preparation for the treatment of psychoses, schizophrenia (positive as well as negative symptoms), anxiety, depression, sleep disturbances, migraine, Parkinson's disease or cocaine abuse.

Patentansprüche

1. Trans-Isomere von 1-Piperazino-1,2-dihydroindenverbindungen mit der allgemeinen Formel I:



I

15 worin

X Wasserstoff, ein Halogen, eine Trifluormethyl- oder eine C₁₋₄-Alkylgruppe ist;

Y Wasserstoff oder ein Halogen ist;

Ar eine Phenylgruppe oder eine mit einem Halogen substituierte Phenylgruppe ist, oder Ar eine Thienylgruppe ist;

R¹ Wasserstoff, eine C₁₋₄-Alkylgruppe oder eine mit einer Hydroxygruppe substituierte C₁₋₄-Alkylgruppe ist;

R² eine C₁₋₄-Alkylgruppe ist; oder

R¹ und R² zusammen mit den Stickstoff- bzw. Kohlenstoffatomen, an welchen sie befestigt sind, einen Piperidinoring bilden, welcher mit dem Piperazinring verschmolzen ist, wobei der Piperidinoring gegebenenfalls mit einer Hydroxygruppe substituiert sein kann;

R³ Wasserstoff oder eine C₁₋₄-Alkylgruppe ist; oder

R² und R³ zusammen mit dem Kohlenstoffatom, an welchem sie befestigt sind, einen 3- bis 7-gliedrigen Spirocycloalkylring bilden;

unter der Voraussetzung, daß R² und R³ keinen Ring bilden, wenn R¹ und R² zusammen einen Ring bilden;

wie auch pharmazeutisch verträgliche Säureadditionssalze davon.

2. Eine Verbindung gemäß Anspruch 1, welche dadurch gekennzeichnet ist, daß

X Wasserstoff, ein Chlor-, Brom- oder Fluoratom, eine Methyl- oder Trifluormethylgruppe ist;

Y Wasserstoff ist;

Ar eine Phenyl-, Fluorphenyl- oder Thienylgruppe ist;

R¹ Wasserstoff, eine Methyl-, 2-Propyl-, Hydroxypropyl- oder Hydroxyethylgruppe ist;

R² eine Methyl-, Ethyl- oder 2-Propylgruppe ist und R³ Wasserstoff, eine Methyl- oder Ethylgruppe ist; oder

R² und R³ zusammen mit den Kohlenstoffatomen, an welchen sie befestigt sind, einen Spirocyclobutyl- oder einen Spirocyclopentylring bilden.

3. Die Verbindung gemäß Anspruch 1, wobei die Verbindung ist:

Trans-4-[6-Chlor-3-(4-fluorphenyl)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethylpiperazin; 1


EP 0 638 073 B1

- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 2
- Trans-4-[3-Phenyl-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 3
- 5 Trans-2,2-Dimethyl-4-[6-methyl-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl] piperazin; 4
- Trans-4-[6-Methyl-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 5
- Trans-2,2-Dimethyl-4-[6-trifluormethyl-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]piperazin; 6
- 10 Trans-4-[6-Trifluormethyl-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 7
- Trans-4-[6-Brom-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 8
- 15 Trans-4-[5,6-Dichlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 9
- Trans-4-[6-Chlor-3-phenyl-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 10
- Trans-4-[6-Chlor-3-(2-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 11
- 20 Trans-4-[6-Chlor-3-(3-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 12
- Trans-4-[6-Chlor-3-(3-thienyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethylpiperazin; 13
- 25 Trans-4-[6-Chlor-3-(3-thienyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 14
- Trans-4-[4-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 15
- Trans-4-[5-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 16
- 30 Trans-4-[7-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 17
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2-dimethylpiperazin; 18
- 35 Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2-(2-propyl)piperazin; 19+20
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1-methyl-2-(2-propyl)piperazin; 21+22
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-diethylpiperazin; 23
- 40 Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-diethyl-1-methylpiperazin; 24
- Trans-8-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-5-methyl-5,8-diazaspiro[3.5]nonan; 28
- 45 Trans-9-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decan; 29
- Trans-9-[6-Chlor-3-(3-thienyl)-2,3-dihydro-1*H*-inden-1-yl]-6-methyl-6,9-diazaspiro[4.5]decan; 30
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,4-diazaspiro[5.5]undecan; 31
- 50 Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1-methyl-1,4-diazaspiro[5.5]undecan; 32
- 2-[6-Fluor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-octahydropyrido[1,2-*a*]pyrazin; 33
- 55 Trans-2-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-octahydropyrido[1,2-*a*]pyrazin; 34
- 2-[6-Fluor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-octahydropyrido[1,2-*a*]pyrazin-8-ol; 35

- Trans-4-[7-Fluor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 36
- Trans-4-[3-(4-Fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 37
- 5 Trans-4-[6-Fluor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazin; 38
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazinpropanol; 39
- Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-(2-propyl)piperazin; 40
- 10 Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2-methyl-1-(2-propyl)piperazin; 41
- Trans-9-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-6-(2-propyl)-6,9-diazaspiro[4.5]decan; 42
- 15 Trans-4-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazinethanol; 43
- Trans-9-[6-Chlor-3-(4-fluorophenyl)-2,3-dihydro-1*H*-inden-1-yl]-6-(2-hydroxyethyl)-6,9-diazaspiro[4.5]decan; 44
- 20 Trans-4-[6-Chlor-3-(3-thienyl)-2,3-dihydro-1*H*-inden-1-yl]-2,2-dimethyl-1-piperazinethanol; 45.
4. Ein pharmazeutisches Präparat, welches dadurch gekennzeichnet ist, daß es wenigstens eine Verbindung gemäß Anspruch 1 zusammen mit einem pharmazeutisch verträglichen Träger oder Verdünnungsmittel umfaßt.
- 25 5. Ein pharmazeutisches Präparat gemäß Anspruch 4, welches dadurch gekennzeichnet ist, daß die Verbindung gemäß Anspruch 1 als ein reines Enantiomer, ein Racemat oder irgendeine andere Mischung der zwei Enantiomeren vorliegt.
6. Verwendung einer Verbindung gemäß Anspruch 1 zur Herstellung eines pharmazeutischen Präparats für die
- 30 Behandlung von Psychosen, Schizophrenie (positive wie auch negative Symptome), Beklemmung, Depression, Schlafstörungen, Migräne, Parkinson Krankheit oder Kokainmißbrauch.

Revendications

- 35 1. Isomères trans des composés de 1-pipérazino-1,2-dihydroindène ayant la formule générale I:



50 dans laquelle

- X est un atome d'hydrogène ou d'halogène ou un groupe trifluorométhyle ou alkyle en C₁-C₄;
Y est un atome d'hydrogène ou d'halogène;
Ar est un groupe phényle ou un groupe phényle substitué par halogène, ou Ar est un groupe thiényle;
55 R¹ est un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ou alkyle en C₁-C₄ substitué par hydroxy;
R² est un groupe alkyle en C₁-C₄; ou
R¹ et R² forment ensemble, avec les atomes d'azote et de carbone respectifs auxquels ils sont liés, un cycle pipéridino condensé avec le cycle pipérazine, ce cycle pipéridino pouvant éventuellement être substitué par

hydroxy;

R³ est un atome d'hydrogène ou un groupe alkyle en C₁-C₄; ou

R² et R³ forment ensemble, avec l'atome de carbone auquel ils sont liés, un cycle spirocycloalkyle de 3 à 7 chaînons;

sous réserve que R² et R³ ne puissent pas former un cycle lorsque R¹ et R² forment ensemble un cycle; ainsi que leurs sels d'addition d'acides pharmaceutiquement acceptables.

2. Composé selon la revendication, caractérisé en ce que

X est un atome d'hydrogène, de chlore, de brome ou de fluor ou un groupe méthyle ou trifluorométhyle;

Y est un atome d'hydrogène;

Ar est un groupe phényle, fluorophényle ou thiényl;

R¹ est un atome d'hydrogène ou un groupe méthyle, 2-propyle, hydroxypropyle ou hydroxyéthyle;

R² est un groupe méthyle, éthyle ou 2-propyle et R³ est un atome d'hydrogène ou un groupe méthyle ou éthyle;

ou

R² et R³ forment ensemble, avec l'atome de carbone auquel ils sont liés, un cycle spirocyclobutyle ou spirocyclopentyle.

3. Composé selon la revendication 1, ce composé étant:

la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthylpipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[3-phényl-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-2,2-diméthyl-4-[6-méthyl-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-pipérazine;
 la trans-4-[6-méthyl-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-2,2-diméthyl-4-[6-trifluorométhyl-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]pipérazine;
 la trans-4-[6-trifluorométhyl-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-bromo-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[5,6-dichloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-chloro-3-phényl-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-chloro-3-(2-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-chloro-3-(3-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-chloro-3-(3-thiényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthylpipérazine;
 la trans-4-[6-chloro-3-(3-thiényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[4-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[5-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[7-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2-diméthylpipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2-(2-propyl)-pipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1-méthyl-2-(2-propyl)pipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diéthylpipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diéthyl-1-méthylpipérazine;
 le trans-8-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-5-méthyl-5,8-diazaspiro[3.5]nonane;
 le trans-9-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-6-méthyl-6,9-diazaspiro[4.5]décane;
 le trans-9-[6-chloro-3-(3-thiényl)-2,3-dihydro-1H-indène-1-yl]-6-méthyl-6,9-diazaspiro[4.5]décane;
 le trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,4-diazaspiro[5.5]undécane;
 le trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1-méthyl-1,4-diazaspiro[5.5]undécane;
 la 2-[6-fluoro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]octahydropyrido[1,2-a]pyrazine;
 la trans-2-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]octahydropyrido[1,2-a]pyrazine;
 le 2-[6-fluoro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]octahydropyrido[1,2-a]pyrazine-8-ol;
 la trans-4-[7-fluoro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 la trans-4-[6-fluoro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-1,2,2-triméthylpipérazine;
 le trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthyl-1-pipérazinepropanol;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthyl-1-(2-propyl)pipérazine;
 la trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2-méthyl-1-(2-propyl)pipérazine;
 le trans-9-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-6-(2-propyl)-6,9-diazaspiro[4.5]décane;
 le trans-4-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthyl-1-pipérazine-éthanol;

le trans-9-[6-chloro-3-(4-fluorophényl)-2,3-dihydro-1H-indène-1-yl]-6-(2-hydroxyéthyl)-6,9-diazaspiro[4.5]décane;

le trans-4-[6-chloro-3-(3-thiényl)-2,3-dihydro-1H-indène-1-yl]-2,2-diméthyl-1-pipérazine-éthanol.

- 5 4. Préparation pharmaceutique, caractérisée en ce qu'elle comprend au moins un composé selon la revendication 1 avec un support ou un diluant pharmaceutiquement acceptable.
- 10 5. Préparation pharmaceutique selon la revendication 4, caractérisée en ce que le composé selon la revendication 1 est présent sous forme d'un énantiomère pur, d'un racémate ou d'un autre mélange quelconque des deux énantiomères.
- 15 6. Utilisation d'un composé selon la revendication 1 pour la fabrication d'une préparation pharmaceutique destinée au traitement de psychoses, de la schizophrénie (symptômes positifs et négatifs), de l'anxiété, de la dépression, des troubles du sommeil, de la migraine, de la maladie de Parkinson ou de la cocaïnomanie.

20

25

30

35

40

45

50

55